OPKO Health, Inc. (NASDAQ:OPK) CEO Buys $198,750.00 in Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 125,000 shares of the business’s stock in a transaction that occurred on Friday, December 13th. The shares were bought at an average cost of $1.59 per share, with a total value of $198,750.00. Following the completion of the purchase, the chief executive officer now directly owns 212,536,477 shares of the company’s stock, valued at $337,932,998.43. This represents a 0.06 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Wednesday, December 11th, Phillip Md Et Al Frost acquired 500,000 shares of OPKO Health stock. The shares were bought at an average cost of $1.56 per share, with a total value of $780,000.00.
• On Friday, November 29th, Phillip Md Et Al Frost bought 199,072 shares of OPKO Health stock. The stock was purchased at an average cost of $1.53 per share, for a total transaction of $304,580.16.
• On Friday, November 22nd, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The stock was purchased at an average price of $1.59 per share, for a total transaction of $159,000.00.
• On Thursday, November 14th, Phillip Md Et Al Frost purchased 100,000 shares of OPKO Health stock. The shares were purchased at an average price of $1.62 per share, with a total value of $162,000.00.
• On Friday, November 8th, Phillip Md Et Al Frost bought 280,183 shares of OPKO Health stock. The shares were purchased at an average price of $1.50 per share, with a total value of $420,274.50.

OPKO Health Stock Performance

Shares of NASDAQ:OPK opened at $1.59 on Monday. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. OPKO Health, Inc. has a 12 month low of $0.85 and a 12 month high of $1.76. The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of -8.37 and a beta of 1.62. The firm’s 50-day moving average is $1.53 and its 200 day moving average is $1.47.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on OPK shares. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target on shares of OPKO Health in a research note on Thursday, September 26th. Piper Sandler reaffirmed an “overweight” rating and issued a $3.00 price target on shares of OPKO Health in a report on Tuesday, September 17th. Finally, Barrington Research reissued an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a research note on Friday, November 8th.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of OPK. CIBC Asset Management Inc boosted its holdings in OPKO Health by 79.1% during the 2nd quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 8,978 shares during the period. FMR LLC lifted its position in shares of OPKO Health by 103.6% during the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 11,089 shares during the last quarter. Algert Global LLC purchased a new stake in shares of OPKO Health during the second quarter valued at $44,000. Orion Portfolio Solutions LLC purchased a new position in OPKO Health in the 3rd quarter worth about $45,000. Finally, Private Advisor Group LLC lifted its holdings in OPKO Health by 242.7% during the 3rd quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 25,000 shares in the last quarter. Institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.